Novaliq is a biopharmaceutical company focused on the development and commercialization of innovative ophthalmological therapies. The company's goal is to revolutionize the treatment of eye diseases by developing novel, best-in-class products based on its proprietary EyeSol® technology. EyeSol® is the world's first water-free technology for ophthalmological products and enables drugs to be administered more effectively and improves patient tolerability.
Novaliq's main focus is on developing therapies for unmet medical needs in the field of ophthalmology. The company has a broad pipeline of product candidates focused on various indications, including dry eye, glaucoma and diabetic retinopathy. Key products include NovaTears®, marketed as EvoTears™ in Europe, a tear film stabilizer for the treatment of dry eyes, as well as VEVYE™ (CyclASol®) and MIEBO™ (NOV03), both of which are FDA-approved for the treatment of dry eyes and are distributed through partners.
Novaliq's mission is to fully exploit the possibilities of eye treatment and improve the lives of patients with eye diseases. The company relies on innovation, scientific excellence and close cooperation with leading academic and industrial partners to achieve its goals.
Novaliq attaches great importance to the safety and efficacy of its products. The company uses only high-purity substances and raw materials from qualified manufacturers and conducts extensive preclinical and clinical studies to ensure the safety and tolerability of its products. The EyeSol® technology is based on semifluorinated alkanes (SFAs), which are characterized by excellent biocompatibility and a very good safety profile. SFAs are not metabolized in the human body and are physically, chemically and physiologically inert.
Novaliq is committed to sustainable development and takes ecological aspects into account in the development and manufacture of its products. The company uses environmentally friendly materials and processes to minimize the impact on the environment.
